Harbour BioMed gets rights to two HanAll compounds in Greater China
Executive Summary
HanAll Biopharma Co. Ltd. (majority owned by Daewoong) licensed Harbour BioMed rights to develop, manufacture, and commercialize two programs in Greater China, including Hong Kong, Macau, and Taiwan.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice